Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Phase 2

Recruiting

Conditions: Peripheral T Cell Lymphoma
Epigenetic Repression

Interventions: Drug: Chidamide
Drug: Azacitidine
Drug: liposomal mitoxantrone
Drug: prednisone

First Posted Date: 2023-07-25

Last Posted Date: 2024-12-30

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 37

Registration Number: NCT05958719

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Phase 1

Withdrawn

Conditions: Diffuse Large B Cell Lymphoma
Transformed Indolent Non-Hodgkin's Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma

Interventions: Drug: FT596
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Rituximab
Drug: Bendamustine

First Posted Date: 2023-07-06

Last Posted Date: 2023-07-06

Lead Sponsor: Fate Therapeutics

Registration Number: NCT05934097

The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis

Phase 2

Completed

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Drug: Budesonide
Drug: Saline
Drug: Prednisone

First Posted Date: 2023-07-05

Last Posted Date: 2023-07-05

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 120

Registration Number: NCT05931744

Locations: 🇪🇬
Kafrelsheikh University hospital, Kafrelsheikh, Egypt

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Phase 2

Recruiting

Conditions: Lung Diseases
Bronchiolitis Obliterans
Chronic Graft Versus Host Disease
Bronchiolitis Obliterans Syndrome

Interventions: Drug: Belumosudil
Drug: Fluticasone
Drug: Azithromycin
Drug: Prednisone
Drug: Montelukast

First Posted Date: 2023-06-28

Last Posted Date: 2024-08-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT05922761

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Effect of Short-term Prednisone Therapy on C-reactive Protein in Patients With Acute Heart Failure

Not Applicable

Recruiting

Conditions: Acute Heart Failure

Interventions: Drug: Prednisone

First Posted Date: 2023-06-23

Last Posted Date: 2024-01-23

Lead Sponsor: Heart Initiative

Target Recruit Count: 120

Registration Number: NCT05916586

Locations: 🇦🇲
"Mikaelyan" Surgery Institute, Yerevan, Armenia
🇦🇲
"Armenia" Republican Medical Center, Yerevan, Armenia
🇦🇲
Erebouni Medical Center, Yerevan, Armenia

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Prednisone

First Posted Date: 2023-06-13

Last Posted Date: 2024-03-07

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 20

Registration Number: NCT05901519

Locations: 🇺🇸
Rogel Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Bendamustine
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2023-06-12

Last Posted Date: 2023-06-12

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 332

Registration Number: NCT05899621

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Phase 1

Recruiting

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Metastatic Melanoma
Metastatic Merkel Cell Carcinoma
Unresectable Basal Cell Carcinoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Metastatic Carcinoma in the Skin
Metastatic Basal Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Ipilimumab
Procedure: Kidney Biopsy
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Drug: Prednisone
Drug: Sirolimus

First Posted Date: 2023-06-09

Last Posted Date: 2024-12-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT05896839

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 21 locations

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Phase 2

Not yet recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2023-06-05

Last Posted Date: 2023-07-27

Lead Sponsor: Liaoning Tumor Hospital & Institute

Target Recruit Count: 30

Registration Number: NCT05887726

Locations: 🇨🇳
Xing Xiaojing, Shenyang, Liaoning, China

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Phase 2

Recruiting

Conditions: Relapsed Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Drug: Epcoritamab
Drug: Investigation agent 2
Drug: Investigation agent 3
Drug: Lenalidomide
Drug: Rituximab
Drug: Obinutuzumab
Drug: Bendamustine
Drug: Vincristine
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2023-05-08

Last Posted Date: 2023-11-29

Lead Sponsor: University of Birmingham

Target Recruit Count: 284

Registration Number: NCT05848765

Locations: 🇬🇧
Cardiff and vale University LHB, Cardiff, United Kingdom
🇬🇧
Belfast Health & Social Care Trust, Belfast, United Kingdom
🇬🇧
NHS Grampian, Aberdeen, United Kingdom

and more 22 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy